Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension
Pulmonary hypertension (PH) is characterized by pulmonary vascular remodeling and associated with adverse outcomes. In patients with PH, plasma aldosterone levels are elevated, suggesting that aldosterone and its receptor, the...
MSc Program Medical Sciences – Cardiovascular Research
We are proud to participate in a newly established program training the cardiovascular scientists of tomorrow: The English-language MSc Medical Sciences – Cardiovascular Research is a 1-year program, combining taught (first term)...
ADMIRE Network Virtual Forum
The ADMIRE network organizes a virtual lecture series that aims to strengthen the exchange between scientists working on aldosterone, the mineralocorticoid receptor, or related topics worldwide. The forum is open...
Epigenetic inhibitors attenuate pathological gene expression in cardiomyocytes
Epigenetic modulators have been proposed as promising new drug targets to treat adverse remodeling in heart failure. Here, we evaluated the potential of 4 epigenetic drugs, including the pan-BRD (bromodomain-containing...
BJP Themed Issue: Therapeutic targeting of the aldosterone–mineralocorticoid receptor signaling pathway
During the past few years enormous research activities substantially advanced our understanding of the molecular, cellular, and pathophysiological functions of the MR. The British Journal of Pharmacology now publishs a...
Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms
MR antagonists have proven to be highly efficient in patients with heart failure and reduced ejection fraction, and they are a cornerstone of contemporary therapy. In the past decade, a series of...